BioSpace News Archive

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that it will present the clinical development schedule for its Sepsis, COVID-19 and Solid Cancer programs during a fireside chat at H.C. Wainwright’s 6th Annual Israel Conference.

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of cancers, today announced new efficacy and safety data from the ongoing Phase 1/2 clinical study of INT230-6, the Company’s lead product candidate.

UroGen Pharma Ltd. announced that the Centers for Medicare & Medicaid Services has established a permanent and product-specific J-code for Jelmyto® for pyelocalyceal solution that will take effect on January 1, 2021.

Aytu BioScience, Inc. announced today that management will present a corporate overview at the Jefferies 2020 Virtual London Healthcare Conference on Wednesday, November 18 at 1:45pm ET / 6:45pm GMT.

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will today present an updated clinical & translational analysis from its Phase II bemcentinib and pembrolizumab combination study (BGBC008) in advanced non-small cell lung cancer (NSCLC),

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey, Chief Executive Officer, and Terry Coelho, Chief Financial Officer, will participate in the virtual Southwest IDEAS Investor Conference on November 18, 2020.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 6th Annual Israel Conference.

MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovascular Registry operated by Veradigm®, an Allscripts (NASDAQ: MDRX), business unit. The registry will support MyoKardia’s post-marketing safety and effectiveness study (DISCOVER-HCM) of mavacamten, an investigational the

The collaboration will develop an innovative genomic-based clinical treatment platform The goal of the collaboration is to accelerate the R&D and commercialization of innovative medicines

The 2021 OBIO Investment Summit national call for applications from health science companies that are seeking Series A or beyond investments is now open.